FDA OKs new use for J&J’s Xarelto

The FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical’s blood thinner XARELTO (rivaroxaban) for the prevention of venous thromboembolism (blood clots) in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

The new indication is the eighth in the U.S.

Related ticker: Bayer (OTCPK:BAYRY)

https://seekingalpha.com/news/3505463-fda-oks-new-use-j-and-js-xarelto